Recent Company News

• 08:19 PM ET May 18, 2026
  

  Notice to Convene Evaxion Annual General Meeting

• 07:43 AM ET May 07, 2026
  

  Evaxion AS reports Q1 EPS ($0.01) vs FactSet ($0.01) [1 est] ($4.41, 0.00)

• 07:30 AM ET May 07, 2026
  

  Evaxion announces business update and first quarter 2026 financial results

• 07:59 AM ET May 04, 2026
  

  Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

• 08:00 AM ET Apr 27, 2026
  

  Evaxion promotes Birgitte Rono to joint role of Chief Scientific and Chief Operating Officer

• 03:13 PM ET Apr 17, 2026
  

  Evaxion's AI-Immunology platform demonstrates 86% vaccine target precision in Phase 2 personalized cancer vaccine trial ($4.39, +0.25)

• 03:04 PM ET Apr 17, 2026
  

  Evaxion AS announces presentation of new data on its AI-Immunology platform in glioblastoma ($4.45, +0.31)

• 11:30 AM ET Apr 16, 2026
  

  Evaxion concludes Annual General Meeting

• 08:06 AM ET Apr 07, 2026
  

  Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 ($3.73, 0.00)

• 04:06 PM ET Mar 09, 2026
  

  Evaxion AS assumed buy at Jones ($3.08, 0.00)